Unravelling the Selectivity of 6,7-Dimethyl Quinoxaline Analogs for Kinase Inhibition: An Insight towards the Development of Alzheimer's Therapeutics

12-Hydroxy-Lauric Acid Tethered Self-Assembled Heterochiral Diphenylalanine-Based Mechanoresponsive and Proteolytically Stable Hydrogel: A Dual Player for Handling Cancer and Bacterial Challenges

Deciphering the most promising strategy for the evolution of cancer patient management remains a multifaceted, challenging affair to date. Additionally, such approaches often lead to microbial infections as side effects, probably due to the compromised immunity of the patients undergoing such treatment. Distinctly, this work delineates a rational combinatorial strategy harnessing stereogenic harmony in the diphenylalanine fragment, tethering it to an amphiphile 12-hydroxy-lauric acid at the N-terminus (compounds I-III) such that a potential therapeutic could be extracted out from the series. Aligned to the goal, the cytotoxic properties and cell viability of the compounds were investigated using two distinct cell lines: MCF-7 (human breast cancer cell) and HEK 293 (human embryonic kidney). Our rigorous investigations revealed that compounds I-III exhibited substantial cytotoxic impact on the MCF7 cell line. But from a pool of three constructs, compound III (12-hydroxy-lauric acid -d-Phe-l-Phe-OH) showed better selectivity toward cancerous MCF7 over normal HEK 293 in comparison to others, backed by computational calculations. Henceforth, it was fished out from the series and used for its elaborate anticancer activities using cell reactive oxygen species generation, DNA fragmentation, and caspase-dependent gene expression employing extrinsic and intrinsic apoptotic factors as well as inflammatory biomarkers, namely, TNF-α and IL1-β. We anticipated that compound III, possessing mechanoresponsiveness and a nanofibrillar network, could be administered in patients with injections because of its shear-thinning properties. Moreover, the optimum partition coefficient of compound III might have allowed the scaffold to penetrate the cellular membranes and form a dilactate complex (compound VI) when exposed to the accumulated lactates/lactic acids, a common phenomenon observed within the hypoxic cancerous tumor cores, in accordance with the Warburg mechanism, thereby evading the cytotoxicity within normal cells. Besides, the supramolecular β-sheets of compound III manifest substantial antimicrobial efficacy against the common pathogens, two Gram-positive bacteria, S. aureus and B. subtilis, two Gram-negative bacteria, E. coli and P. aeruginosa, and a fungus, C. albicans, along with proteolytic stability and high mechanical strength at physiological pH. Overall, we speculate that the discovery of these multifunctional bioinspired materials holds future promise as preferential therapeutics for the remediation of immune-susceptible cancer patients, afflicted by microbial infections arising alone or as side effects of chemotherapeutic medications.

Recent Methods for the Synthesis of Quinoxaline Derivatives and their Biological Activities

Quinoxaline derivatives have been incorporated into numerous marketed drugs used for the treatment of various diseases. Examples include glecaprevir (Mavyret), voxilaprevir (Vosevi), Balversa (L01EX16) (erdafitinib), carbadox, XK469R (NSC698215), and becampanel (AMP397). These quinoxaline derivatives exhibit a diverse range of pharmacological activities, including antibacterial, antitubercular, antiviral, anti-HIV, anti-inflammatory, antifungal, anticancer, antiproliferative, antitumor, kinase inhibition, antimicrobial, antioxidant, and analgesic effects. Recognizing the significance of these bioactive quinoxaline derivatives, researchers have dedicated their efforts to developing various synthetic methods for their production. This review aimed to compile the most recent findings on the synthesis and biological properties of quinoxaline derivatives from 2015 to 2023.

Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases

The CLKs (Cdc2-like kinases) belong to the dual-specificity protein kinase family and play crucial roles in regulating transcript splicing via the phosphorylation of SR proteins (SRSF1-12), catalyzing spliceosome molecular machinery, and modulating the activities or expression of non-splicing proteins. The dysregulation of these processes is linked with various diseases, including neurodegenerative diseases, Duchenne muscular dystrophy, inflammatory diseases, viral replication, and cancer. Thus, CLKs have been considered as potential therapeutic targets, and significant efforts have been exerted to discover potent CLKs inhibitors. In particular, clinical trials aiming to assess the activities of the small molecules Lorecivivint on knee Osteoarthritis patients, and Cirtuvivint and Silmitasertib in different advanced tumors have been investigated for therapeutic usage. In this review, we comprehensively documented the structure and biological functions of CLKs in various human diseases and summarized the significance of related inhibitors in therapeutics. Our discussion highlights the most recent CLKs research, paving the way for the clinical treatment of various human diseases.

An Overview of the Biological Evaluation of Selected Nitrogen-Containing Heterocycle Medicinal Chemistry Compounds

Heterocyclic compounds are a class of compounds of natural origin with favorable properties and hence have major pharmaceutical significance. They have an exceptional adroitness favoring their use as diverse smart biomimetics, in addition to possessing an active pharmacophore in a complex structure. This has made them an indispensable motif in the drug discovery field. Heterocyclic compounds are usually classified according to the ring size, type, and the number of heteroatoms present in the ring. Among different heterocyclic ring systems, nitrogen heterocyclic compounds are more abundant in nature. They also have considerable pharmacological significance. This review highlights recent pioneering studies in the biological assessment of nitrogen-containing compounds, namely: triazoles, tetrazoles, imidazole/benzimidazoles, pyrimidines, and quinolines. It explores publications between April 2020 and February 2022 and will benefit researchers in medicinal chemistry and pharmacology. The present work is organized based on the size of the heterocyclic ring.